Table 1 Clinical and functional data for patients (n = 27) with interstitial pulmonary fibrosis (IPF)
From: [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis
Characteristics | |
 Age (years) | 65.3 ± 12.4 |
 Duration of disease (years) | 2.9 ± 2.7 |
 Sex ratio (M/F), no. | 22/5 |
 Mortality (%) | 44% (12/27) |
 Survival (years) | 1.5 ± 1.2 |
 Duration of follow-up (years) | 3.4 ± 1.2 |
Smoking status, n (pack-years) | |
 Current smoker | 4 (45 ± 5) |
 Former smoker | 12 (27 ± 12) |
 Never smoker | 11 |
Lung function tests | |
 FVC (L) | 2.3 ± 0.9 |
 FVC (% predicted) | 71 ± 26 |
 DLCO (% predicted) | 41 ± 16 |
 Distance traveled during 6MWT (meters) (meters) (meters)=21) | 457 ± 76 |
 PaO2 (mmHg) | 69.2 ± 9.1 |
 PaCO2 (mmHg) | 36.8 ± 2.6 |
 Bronchoalveolar lavage cytology (n = 19) Cellularity (x103/mL) | 263 ± 19 |
 Macrophages (%) | 62.0 ± 4.6 |
 Lymphocytes (%) | 9.3 ± 1.6 |
 Neutrophils (%) | 22.2 ± 5.0 |
 Eosinophils (%) | 2.5 ± 1.6 |